Home
Sign In
About
Curriculum
Activity Information
Target Audience
Learning Objectives
Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Course materials have been developed for use outside of the United States.
|
 |
|
|
|
|
|
|
Indications for Successful Iron Overload Treatments and Monitoring: Myelodysplastic Syndromes
Transfusion-dependent myelodysplastic syndromes (MDS) patients with favorable prognoses and/or stable disease are at risk of developing clinical consequences of iron overload and can benefit from iron chelation therapy. In this webcast, Dr. Gattermann discusses the cardiac morbidity resulting from iron overload in patients with MDS, indications for and benefits of chelation therapy, selection of appropriate MDS patients for treatment, and treatment guidelines for the initiation and duration of iron chelation therapy.
|
|
Faculty
|
|
|
Norbert Gattermann, MD, PhD
Department of Haematology,
Oncology and Clinical Immunology
Heinrich-Heine-University
Dusseldorf, Germany
|
|
|
Target Audience
This activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.
|
Learning Objectives
After participating in this activity, participants should be better able to:
- Apply knowledge of the prognosis of transfusion-dependent MDS patients and the guidelines for initiating chelation therapy to identify which patients are at risk of the clinical consequences of iron overload and to determine when to initiate appropriate chelation therapy.
|
Disclosure Information
Norbert Gattermann, MD, PhD, is on the speakers bureau of and on the advisory boards for Novartis Pharmaceuticals Corporation and Pharmion Corporation. Prof. Gatterman has disclosed that he will not reference any unlabeled/unapproved uses of drugs or devices.
|
|
|
|
|
|
|
